What important historical amendments have been made to Hong Kong’s pharmaceutical licensing legislation, and how have they affected the industry?

Hong Kong’s pharmaceutical licensing legislation is not static; it continues to evolve in response to changing circumstances and public health needs. Several important amendments have had a far-reaching impact on the industry. For example, the Chinese Medicine Ordinance (Cap. 549), enacted in 1997, was a landmark reform. It brought Chinese medicine within a statutory regulatory framework for the first time, requiring Chinese medicine traders to be licensed and proprietary Chinese medicines to be registered, and fundamentally changing an industry that had previously lacked uniform standards. In recent years, in response to the growing issues of cross-border e-commerce and personal imports of medicines, the Government has reviewed and tightened the exemptions for medicine imports under the Import and Export Ordinance (Cap. 60). Requirements for pharmacovigilance have also been strengthened, requiring licence holders to establish more comprehensive systems for reporting adverse drug reactions. Overall, the trend is towards increasingly scientific, systematic and stringent regulation. For the industry, this means higher compliance costs, but it has also encouraged professionalisation and the development of a more competitive sector, strengthening the industry’s reputation and international competitiveness.